Original Article
Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients
Abstract
Background: Assessment of serum extracellular matrix (ECM) metalloproteinase MMP-2 and tissue inhibitor of matrix metalloproteinase TIMP-2 concentrations in non-small cell lung carcinoma (NSCLC) patients considering TNM staging. Assessment of the prognostic value of MMP-2 and TIMP-2 concentrations in NSCLC patients.
Methods: The study group consisted of 81 NSCLC patients (24 females and 57 males) aged 46 to 86 years (mean age of 67±8.2 years). The control group comprised 39 randomly selected patients (20 females and 19 males) aged 27 to 73 years (mean age of 47±15.0 years) in whom primary lung cancer was excluded and who were operated on for a calculus of the gallbladder without cholecystitis. Blood serum MMP-2 and TIMP-2 concentrations were determined using an enzyme-linked immunosorbent assay (ELISA)-based test.
Results: Statistically significantly higher mean MMP-2 and TIMP-2 concentrations were found in NSCLC patients compared to those in the control group (P<0.001). Statistically significant differences in MMP-2 and TIMP-2 concentrations between patients with T1 and T2 tumour and patients with T3 and T4 tumour, as well as between the group without metastases (N0) and the group with metastases to lymph nodes were demonstrated. Moreover, a significant fall in mean MMP-2 and TIMP-2 concentrations was observed in the postoperative compared to preoperative period (P<0.001).
Conclusions: Serum MMP-2 and TIMP-2 concentrations in NSCLC patients correlated with the tumour size and presence of metastases to lymph nodes and thus may serve as an auxiliary parameter indicating probability of a more advanced stage of lung cancer.
Methods: The study group consisted of 81 NSCLC patients (24 females and 57 males) aged 46 to 86 years (mean age of 67±8.2 years). The control group comprised 39 randomly selected patients (20 females and 19 males) aged 27 to 73 years (mean age of 47±15.0 years) in whom primary lung cancer was excluded and who were operated on for a calculus of the gallbladder without cholecystitis. Blood serum MMP-2 and TIMP-2 concentrations were determined using an enzyme-linked immunosorbent assay (ELISA)-based test.
Results: Statistically significantly higher mean MMP-2 and TIMP-2 concentrations were found in NSCLC patients compared to those in the control group (P<0.001). Statistically significant differences in MMP-2 and TIMP-2 concentrations between patients with T1 and T2 tumour and patients with T3 and T4 tumour, as well as between the group without metastases (N0) and the group with metastases to lymph nodes were demonstrated. Moreover, a significant fall in mean MMP-2 and TIMP-2 concentrations was observed in the postoperative compared to preoperative period (P<0.001).
Conclusions: Serum MMP-2 and TIMP-2 concentrations in NSCLC patients correlated with the tumour size and presence of metastases to lymph nodes and thus may serve as an auxiliary parameter indicating probability of a more advanced stage of lung cancer.
